NeuroTimone Facility (PFNT)

The PFNT Facility is a coherent set of exploration tools in neurobiology allowing research at the molecular, cellular and integrated levels.


  1. Three members of INP presented their work on Glioma during the 14th EANO annual meeting held in Lyon (19 - 22 September, 2019)

    During the 14th EANO annual meeting 3 members of INP team #8 presented their work on Glioma in a plenary conference «CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDHmutant gliomas» Dominique Figarella Branger, a short talk «Plasmatic differential scanning fluorimetry profiles discriminate glioma patients from healthy controls» Emeline Tabouret and two posters «P11.06: Non epigenetic effect of vorinostat in glioblastoma cells» and «EB1-dependant long survival of glioblastoma cancer stem-like cells tumor

  2. Nadia Merad Coliac and Maxime Bonnet joined the NOSE team

    Nadia Merad Coliac, plastic designer, joined the NOSE (Nasal Olfactory Stemness and Epigenesis) team, as an Associate researcher. At the crossroads of several disciplines, she develops an experimental work of art and science, in the field of bioluminescence. She is considering a therapeutic application in patients with autism spectrum disorders (ASD). Recently, Nadia published Lumière vivante - Théorie et pratique de la bioluminescence (Living light - theory and use of bioluminescence) - L’Harmattan eds.

  3. New publication from the GlioME Team (INP team 8) in Cancers pointing at A2B5 as an attractive therapeutic target for glioblastomas.
  4. F. Devred and E. Tabouret presented their research work at the annual Canceropole PACA meeting
  5. INP team 8 and 9 and PINT members presented their work at the 4th French Microtubule Network

    INP team 8 and 9 and PINT members being part of the French Microtubule Network, several members presented their work at the 4th French Microtubule Network gathering in Rennes on the 1srt and 2nd july 2019, in the  "Microtubules and their regulators : new therapeutic targets" session and the "Microtubules, assembly and regulation" session. Pascale Barbier presented her work "", Raphael Berges his work "Proscillaridin A exerts anti-tumor effects through"GSK3 activation and alteration of microtubule dynamics in glioblastoma" and François Devred a new method of "Functional screening of therapeutic agents and targets using nanoDSF "

  6. CNRS and Aix-Marseille University sign Agreement with the SME Vect-Horus on the intellectual property

    An article entitled "Le CNRS et Aix-Marseille Université signent un accord avec la PME Vect-Horus sur la propriété intellectuelle",  published in the CNRS Innovation Letter of 20 June 2019 and relayed by the INSB site, features the agreement signed by CNRS, AMU and Vect-Horus establishing the intellectual property rights regime and the exploitation of patents.

  7. The GlioME team published a new article in Stem Cells and one eye-catch figure of their paper was selected for the cover image of the June journal issue!

    Our last work on IAPs : "Inhibitor of Apoptosis Proteins (IAPs) Determines Glioblastoma Stem‐Like Cell Fate in an Oxygen‐Dependent Manner" is now published in Stem Cells. We highlighted that pharmacological inhibition of IAPs by Smac mimetic GDC-0152 was able to decrease glioblastoma stem-like cells viability in hypoxia by decreasing cell proliferation and increasing apoptosis through ATR and TNFα pathways

  8. INP researchers and students massively attended NeuroFrance 2019

    During the last NeuroFrance congress held from May 22 to 24, 2019 at the Palais des Congrès in Marseille, the INP distinguished itself through 20 posters, 4 oral communications, and 1 symposium moderation, not to mention the organization of the "Art in Mind" exhibition, showing not only the richness and quality of his research but also his open-mindedness. 


INP in numbers

  • 126 members
  • 44 researchers
  • 48 research assistants
  • 12 post-docs
  • 11 PhD


Deux nouveaux arrivants dans l'équipe GlioME

L'équipe 8 (GlioME) a le plaisir d'accueillir deux étudiants en Master 2, Anaïs Arathni étudiante en Master Biologie Santé et Emmanuel Snacel-Fazy étudiant en Master Neurosciences. Anaïs travaillera avec Aurélie Tchoghandjian sur la caractérisation des cellules immunitaires recrutées sur le site tumoral suite au traitement par mimétiques de Smac. Emmanuel travaillera avec Chiara Bastiancich sur le microenvironnement de la résection tumorale du glioblastome.


A commentary from Christophe Leterrier in the Journal of Cell Biology

Christophe Leterrier, leader of the NeuroCyto ATIP team, wrote a Spotlight in the Journal of Cell Biology highlighting a nice recent paper from the group of Pei-Lin Cheng in Taiwan. In this article, Lee et al. showed how degradation of the chloride transporter NKCC1 by proteasomes anchored at the AIS have a key role in lowering the intracellular chloride concentration, leading to the perinatal reversal of GABA effect from excitatory to inhibitory.


2019 Retrospective: D. Figarella-Branger from the GlioME team was involved in 5 reference articles on pediatric brain tumours

Thanks to her expertise in the diagnosis of central nervous system tumours arising in children and young adults, Dominique Figarella-Branger from the GlioME team (Team 8) was involved last year in 5 articles published in high-impact factor journals (>18). These articles are becoming references in this field:

- The molecular landscape of ETMR at diagnosis and relapse. Nature. 2019 Dec;576(7786):274-280. PMID: 31802000


"Alzheimer's disease: a year of hope" (La Marseillaise - January 2020)

Maladie d'Alzheimer : une nouvelle année pleine d'espoir. 

In its week-end edition (january the 4th & 5th 2020), the daily newspaper La Marseillaise devoted its "Provence Terre de Science" page to Alzheimer's disease reserach.

On this occasion François Devred (INP team 9 / PINT platform) answered a few questions on the molecular characterization of this complex protein (to be downloaded by clicking here )


New publication of the NeuroCyto team

First work of 2020 work is out for the NeuroCyto team! A collaboration with Matt Rasband’s lab in Nature Communications. This is a significant paper for the axon initial segment field: Matt’s lab used BioID of key AIS proteins for mapping AIS components. Dozens of new candidates for future studies! We performed super-resolution microscopy of several of the newly identified AIS components. IN particular, we showed that Mical3, a protein linking microtubules and actin, forms clusters along the AIS that are not periodically organized along the actin/spectrin scaffold.


New publication from the GlioME Team and the national POLA network (dedicated to high grade oligodendroglioma) pointing at CDKN2A homozygous deletion as a strong adverse prognostic factor in diffuse malignant IDH-mutant gliomas.

In a large cohort of 911 high-grade IDH-mutant gliomas from the French national POLA network, we investigated the prognostic value of the CDKN2A gene homozygous deletion as well as WHO grading criteria (mitoses, microvascular proliferation, and necrosis).

We showed that:
- CDKN2A homozygous deletion characterizes diffuse malignant IDH-mutant gliomas with worst outcome.

- Microvascular proliferation stratifies IDH-mutant gliomas lacking CDKN2A homozygous deletion.